Amikacin-fosfomycin at a five-to-two ratio: Characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3708-3713

  Montgomery, A Bruce ^a   Rhomberg, Paul R ^b   Abuan, Tammy ^a   Walters, Kathie Anne ^a   Flamm, Robert K ^b  

^a Cardeas Pharma   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; AZTREONAM; CEFEPIME; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; MEROPENEM; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG COMBINATION;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPONTANEOUS MUTATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIUM; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; GENETICS; HUMAN; KINETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIA; DNA MUTATIONAL ANALYSIS; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; FOSFOMYCIN; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MUTATION; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84903202002     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02779-13     Document Type: Article

References (27)

1. Koenig SM, Truwit JD. 2006. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin. Microbiol. Rev. 19:637-657. http://dx.doi.org/10.1128/CMR.00051-05. (Pubitemid 44582975)
2. Jiménez P, Torres A, Rodriguez-Roisin R, de la Bellacasa JP, Aznar R, Gatell JM, Agustí-Vidal A. 1989. Incidence and etiology of pneumonia acquired during mechanical ventilation. Crit. Care Med. 17:882-885. http://dx.doi.org/10.1097/00003246-198909000-00007. (Pubitemid 19233317)
3. Kollef MH, Silver P. 1995. Ventilator-associated pneumonia: an update for clinicians. Respir. Care 40:1130-1140.
4. Rello J, Quintana E, Ausina V, Castella J, Luquin M, Net A, Prats G. 1991. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 100:439-444. http://dx.doi.org/10.1378/chest.100.2. 439.
5. Albert M, Friedrich JO, Adhikari NK, Day AG, Verdant C, Heyland DK; Canadian Critical Care Trials Group. 2008. Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia. Secondary analysis of a multicenter randomized trial. J. Crit. Care 23:74-81. http://dx.doi.org/10. 1016/j.jcrc.2008.01.004. (Pubitemid 351400357)
6. Goldberg AE, Malhotra AK, Riaz OJ, Aboutanos MB, Duane TM, Borchers CT, Martin N, Ivatury RR. 2008. Predictive value of bronchoalveolar lavage fluid Gram's stain in the diagnosis of ventilator-associated pneumonia: a prospective study. J. Trauma 65:871-876. http://dx.doi.org/10.1097/TA.0b013e31818481e0.
7. O'Horo JC, Thompson D, Safdar N. 2012. Is the Gram stain useful in the microbiologic diagnosis of VAP? A meta-analysis. Clin. Infect. Dis. 55: 551-561. http://dx.doi.org/10.1093/cid/cis512.
8. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC. 1997. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111:676-685. http://dx.doi.org/10.1378/chest.111.3.676. (Pubitemid 27132946)
9. Pennington JE. 1981. Penetration of antibiotics into respiratory secretions. Rev. Infect. Dis. 3:67-73. http://dx.doi.org/10.1093/clinids/3.1.67.
10. Limbago BM, Rasheed JK, Anderson KF, Zhu W, Kitchel B, Watz N, Munro S, Gans H, Banaei N, Kallen AJ. 2011. IMP-producing carbapenem-resistant Klebsiella pneumoniae in the United States. J. Clin. Microbiol. 49:4239-4245. http://dx.doi.org/10.1128/JCM.05297-11.
11. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect. Dis. 13:785-796. http://dx.doi.org/10. 1016/S1473-3099(13)70190-7.
12. Kollef MH. 2005. What is ventilator-associated pneumonia and why is it important? Respir. Care 50:714-721. (Pubitemid 46187577)
13. Rosenfeld M, Cohen M, Ramsey B. 1997. Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy, and pitfalls. Clin. Pulm. Med. 4:101-112. http://dx.doi.org/10.1097/00045413-199703000-00006.
14. Rodríguez-Rojas A, Couce A, Blázquez J. 2010. Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:4948-4949. http://dx.doi.org/10.1128/AAC.00415-10.
15. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O'Riordan T, Daroowalla F, Richman P. 2008. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit. Care Med. 36:2008-2013. http://dx.doi.org/10.1097/CCM.0b013e31817c0f9e.
16. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ; Nebulized Antibiotics Study Group. 2011. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 184:106-115. http://dx.doi.org/10.1164/rccm.201011-1894OC.
17. Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, Garcia MS. 2012. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 38:263-271. http://dx.doi.org/10.1007/s00134-011-2420-0.
18. Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A. 2 January 2014. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI Investigational eFlow® Inline Nebulizer System in mechanically ventilated patients. J. Aerosol Med. Pulm. Drug Deliv. http://dx.doi.org/10.1089/jamp.2013.1100.
19. Montgomery AB, Rhomberg PR, Abuan T, Walters K-A, Flamm RK. 2014. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens. Antimicrob. Agents Chemother. 58:3714-3719. http://dx.doi.org/10.1128/AAC.02780-13.
20. CLSI. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
21. CLSI. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing:23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Moody J, Knapp C. 2010. Time-kill assay for determining synergy, p 5.10.3.1-5.10.3.6. In Garcia LS, Isenberg HD (ed), Clinical microbiology procedures handbook. ASM Press, Washington, DC.
23. Moody J. 2010. Synergism testing: broth microdilution checkerboard and broth macrodilution methods, p 5.12.1-5.12.23. In Garcia LS, Isenberg HD (ed), Clinical microbiology procedures handbook. ASM Press, Washington, DC.
24. Sader HS, Huynh HK, Jones RN. 2003. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against gram-negative bacilli. Diagn. Microbiol. Infect. Dis. 47:547-550. http://dx.doi.org/10.1016/S0732-8893(03)00158-5. (Pubitemid 37338520)
25. Kiffer CR, Sampaio JL, Sinto S, Oplustil CP, Koga PC, Arruda AC, Turner PJ, Mendes C. 2005. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 52:317-322. http://dx.doi.org/10.1016/j.diagmicrobio.2005.03.003. (Pubitemid 41297570)
26. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340:23-30. http://dx.doi.org/10.1056/NEJM199901073400104. (Pubitemid 29024680)
27. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. 2011. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J. Antimicrob. Chemother. 66:2398-2404. http://dx.doi.org/10.1093/jac/dkr303.